Richards Timothy T. 4

What Happened

• Timothy T. Richards, a director of ClearPoint Neuro, had 12,417 restricted stock units (RSUs) convert into 12,417 shares of CLPT common stock on May 19, 2026. The Form 4 reports the conversion as a derivative transaction (code M). No per-share price or total dollar value is reported in the filing.
• The filing shows both an acquisition (receipt of 12,417 shares) and a simultaneous disposition of 12,417 shares in connection with the derivative conversion. The footnote clarifies this event represents the scheduled settlement of RSUs granted on May 22, 2025.

Key Details

• Transaction date: 2026-05-19; Form 4 filed: 2026-05-21 (filed within the typical two-business-day window).
• Shares reported acquired: 12,417 (conversion of RSUs). Shares reported disposed: 12,417 (listed as derivative disposition).
• Price per share / total value: Not reported (N/A) in the filing.
• Footnote: Grant date of RSUs was May 22, 2025; vesting occurred on the earlier of the first anniversary or the day before the 2026 annual meeting; this filing reflects settlement on the scheduled vesting date.
• Post-transaction total shares owned: Not specified in the filing.
• Transaction code: M = exercise or conversion of a derivative security (here, RSU settlement).

Context

• This is a vesting/settlement of equity compensation, not an open-market buy or sale. Such conversions are routine compensation events for insiders and do not by themselves indicate a buy/sell signal from the insider.
• The filing does not state whether any shares were withheld to cover taxes or other obligations; the simultaneous acquisition and disposition entries are consistent with RSU settlement mechanics but no withholding is explicitly disclosed.